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therapy is commonly used to increase the clinical efficacy of
adoptive T cell therapy (ACT) strategies, however, with severe
toxicity for patients. Conversely, oncolytic adenoviruses are
safe and, when engineered to express interleukin-2 (IL-2)
and tumor necrosis factor alpha (TNF-a), they can achieve
antitumor immunomodulatory effects similar to lymphode-
pletion. Therefore, we compare the safety and efficacy of
such adenoviruses with a cyclophosphamide- and fludara-
bine-containing lymphodepleting regimen in the setting of
ACT. Human adenovirus (Ad5/3-E2F-D24-hTNF-a-IRES-
hIL-2; TILT-123) replication was studied using a Syrian
hamster pancreatic tumor model (HapT1) infused with tu-
mor-infiltrating lymphocytes (TILs). Using the oncolytic virus
instead of lymphodepletion resulted in superior efficacy and
survival. Immune cells responsive to TNF-a IL-2 were studied
using an immunocompetent mouse melanoma model
(B16.OVA) infused with ovalbumin-specific T (OT-I) cells.
Here, the adenovirus approach improved tumor control
together with increased intratumoral Th1 cytokine levels
and infiltration of CD8+ T cells and CD86+ dendritic cells.
Similar to humans, lymphodepleting preconditioning caused
severe cytopenias, systemic inflammation, and damage to vital
organs. Toxicity was minimal in adenovirus- and OT-I-
treated mice. These findings demonstrate that ACT can be
effectively facilitated by cytokine-coding adenovirus without
requiring lymphodepletion, a rationale being clinically inves-
tigated.Received 8 February 2018; accepted 1 June 2018;
https://doi.org/10.1016/j.ymthe.2018.06.001.
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The use of adoptively transferred tumor-infiltrating lymphocytes
(TILs), chimeric antigen receptor (CAR)-, or T cell receptor (TCR)-
modified T cells to treat advanced malignancies has shown encour-
aging results in animal models and in humans.1,2 In hematology, tisa-
genlecleucel (Kymriah) has been approved by the U.S. Food and Drug
Administration (FDA) with outstanding results for the treatment of
CD19+ acute lymphoblastic leukemia.3 In solid tumors, impressive
results have been seen mostly in TIL treatment of melanoma, whereMolecular Therapy Vol. 26 No 9 Septemberefficacy requires both high-dose postconditioning interleukin-2
(IL-2) and high-dose preconditioning chemotherapy.4,5 Without pre-
conditioning, response rates to melanoma TIL therapy were 23%,6
while with lymphodepletion, a 51% response rate has been observed.5
Pre- and postconditioning are now universally used in TIL treatment
of melanoma, and they are frequently used also in other forms of
adoptive T cell therapy (ACT).1
It has been proposed that the depletion of endogenous host immune
cells ensures the survival and proliferation of transferred cells that
otherwise would be suppressed or deprived of key cytokines.7 Lym-
phodepleting preconditioning also acts as a modulator of the tumor
microenvironment, enabling the infiltration and proliferation of
effector cells and antigen-presenting cells (APCs). Thus, the many ef-
fects of lymphodepletion converge on decreasing tumor immunosup-
pression.7 The latter is thought to be the key obstacle to successful
ACT of solid tumors, because the microenvironment of solid tumors
can anergize, exclude, and inhibit the survival and proliferation of
antitumor effector T cells.8,9 The effects of a suppressive tumormicro-
environment are not restricted to T cells but also act on other immune
cell types, such as macrophages.10
Given the favorable clinical outcomes in various trials,4,5,11–13 lym-
phodepleting preconditioning has been integrated into ACT proto-
cols, commonly consisting of a combination of chemotherapeutic
agents.1 Yet, the increase in antitumor efficacy observed in precondi-
tioned patients comes at a cost. Most patients experience severe and
even life-threatening toxicities, such as opportunistic infections or
acute sepsis, resulting from cytopenias caused by chemotherapeu-
tics.5,11–13 These can be particularly challenging for already-debili-
tated cancer patients, narrowing the spectrum of patients that can
be treated with ACT.2018 ª 2018 The American Society of Gene and Cell Therapy. 2243
Molecular TherapyRecently, oncolytic viruses have begun to transition from experi-
mental therapeutics into routine clinical use. Talimogene laherparep-
vec (Imlygic) has been approved by the FDA and the European
Medicines Agency following an impressive increase in durable
response rates in non-resectable melanoma patients,14 and several
other types of oncolytic viruses with different immunological effects
are in development.15 Adenoviruses have been proposed attractive
in this regard since they have strong effects on the adaptive and innate
cellular immune systems.16
Oncolytic adenoviruses target and replicate only in tumor cells, and
oncolytic cell death causes damage-associated molecular pattern
(DAMP) and pathogen-associated molecular pattern (PAMP)
signaling, rewiring the tumor microenvironment to become proin-
flammatory with the alteration of immune cell and cytokine con-
tent.16–18 Consequently, this triggers the immune system to develop
a bispecific response against both the virus and tumor. Antiviral im-
munity helps the generation of antitumor responses against tumor
epitopes (for instance, epitope spreading), which are generally weaker
than evolutionarily conserved antiviral mechanisms.16–18 Tumor epi-
topes are presented after oncolysis, in the context of immunological
danger signals. Accordingly, we previously reported that exploiting
this circuit to deliver cytokines that favor T cell attraction and sur-
vival, such as IL-2 and tumor necrosis factor alpha (TNF-a), enables
ACT in several preclinical models.19–21 Considering the aforemen-
tioned safety hazards of host lymphodepletion and the ability of
armed adenoviruses to achieve similar biological effects in the tumor
microenvironment, we hypothesize that we could use the latter to
replace the former.
Here, we compared the antitumor efficacy and safety of IL-2- and
TNF-a-coding adenoviruses with conventional lymphodepletion in
animals that received ACT. We demonstrate that enabling ACT
with adenovirus established effective antitumor responses, which
were similar or superior to the ones observed in lymphodepleted
animals that received ACT. Moreover, as seen in humans, host lym-
phodepletion caused severe toxicity that was not present in adeno-
virus-treated animals.
RESULTS
Improved Tumor Control Is Associated with Intratumoral
Infiltration of Immune Cells, which Mediate Potent Immunity
against HapT1 Tumors
We studied whether intratumoral administration of TILs and onco-
lytic adenovirus promote effective tumor control and systemic immu-
nity against HapT1 tumors, in comparison to hamsters that were
lymphodepleted prior to TIL infusion (Figure 1A). The semi-permis-
sive nature of the Syrian golden hamster allowed us to study the
oncolytic capability of the human adenovirus coding for IL-2 and
TNF-a. Overall, antitumor efficacy curves demonstrate that animals
that received TIL therapy alone had statistically significant tumor
regressions compared with the vehicle group (vehicle versus TILs,
p < 0.0001; Figure 1B). Adding lymphodepleting preconditioning or
oncolytic adenovirus to TIL therapy resulted in improvement in2244 Molecular Therapy Vol. 26 No 9 September 2018tumor control compared with the vehicle control (vehicle versus
preconditioning + TILs, p < 0.00001; vehicle versus oncolytic
adenovirus + TILs, p < 0.00001; Figure 1B). Adding lymphodepletion
to oncolytic adenovirus treatment did not result in significant gains,
although on the individual tumor level there were fewer escape
variants (Figure S1). Also, response occurred faster with the triple
combination, possibly because there was less inflammatory pseudo-
progression when white blood cells had been eradicated with precon-
ditioning (Figure 1B).
Interestingly, analysis of endpoint tumors demonstrated a progres-
sive increase in the ratio of CD4/CD8 cells in groups with high
tumor control (Figure 1C). In the spleens of hamsters that were pre-
conditioned, we observed a significant decrease of CD8+ and CD4+
cells compared to the oncolytic adenovirus + TIL therapy group
(Figure S2). The latter maintained levels of these cells similar to
the control conditions (oncolytic adenovirus + TILs versus
TILs, not significant [ns]; oncolytic adenovirus + TILs versus
vehicle, ns). Regional lymph nodes revealed high infiltration of
CD8+ and CD4+ cells in hamsters treated with TIL therapy only,
while the other therapies (including the vehicle control) demon-
strated mild alterations. Lymphodepletion also reduced the percent-
age of cells expressing major histocompatibility complex (MHC)
class II in the lymph nodes, while the contrary was observed in
any treatment combination containing adenovirus, including the tri-
ple therapy group. However, no significant changes in the percent-
age of MHC class II cells were observed between the groups. When
we co-cultured endpoint splenocytes from different therapeutic
groups with tumor cell lines, splenocytes from the hamsters that
received the combination of oncolytic adenovirus and TILs were
able to kill more HapT1 cells compared to the preconditioning
groups (oncolytic adenovirus + TILs versus preconditioning +
TILs, p < 0.05; oncolytic adenovirus + TILs versus preconditioning +
oncolytic adenovirus + TILs, p < 0.05; Figure 1D). For other cell
lines there were no differences between the groups, indicating the
cell-specific nature of the immune response generated (Figure 1D).
Adenovirus Therapy Promotes Long-Term Survival of TIL-
Treated Animals
To understand if the oncolytic adenovirus therapy would translate
into improved overall survival compared with lymphodepleted ani-
mals, we conducted a separate long-term hamster survival experiment
(Figure 2A). Considering that TIL therapy can be administered with
different approaches, such as intravenous, intratumoral, and intraper-
itoneal, here TIL therapy was administered systemically (intraperito-
neally), resembling the majority of clinical trials that have used
systemic administration.4,5,11–13,22
When we plotted the overall survival curve of hamsters that were pre-
conditioned with cyclophosphamide and fludarabine, we observed
that approximately 50% of the deaths occurred at early time points
(days 4–9), indicating early complications after chemotherapy
administration (Figure 2B), as seen in humans.5,11–13 Survival of
hamsters in the other therapeutic groups was determined by tumor
Figure 1. Antitumor Efficacy and Systemic Effects of
Local TIL and Oncolytic Adenovirus Therapy of
Hamsters
(A) Hamsters with 5-day-old subcutaneous HapT1 tumors
received a lymphodepleting regimen consisting of cyclo-
phosphamide (550 mg/kg) and fludarabine (100 mg/kg) or
saline intraperitoneally (i.p.). 1  108 virus particles (VPs)
oncolytic adenovirus (OAd) coding for human IL-2 and
TNF-a or PBS was injected intratumorally (i.t.) on day 1
and repeated 4 times. Tumor-infiltrating lymphocytes
(TILs) or RPMI was injected i.t. a day after the first virus
injection. (B) Tumor growth curves from different treatment
groups (n = 5–6). Tumors were measured every 2–3 days
after virus treatment initiation and followed until day 28
when animals were sacrificed and tumors and organs
were collected for further analysis. (C) Ratio of CD4/CD8+
cells obtained by flow cytometric analysis on endpoint
tumors. (D) Mitochondrial activity corresponding to cell
viability obtained by performing MTS assay on co-cultures
of endpoint-pooled splenocytes from each therapeutic
group and tumor cell lines at a ratio of 20:1 splenocy-
tes:tumor cells. Experiment was performed in triplicates.
Data are presented as mean + SEM; *p < 0.05, **p < 0.01,
***p < 0.001, and ****p < 0.0001.
www.moleculartherapy.orgcontrol, and, thus, deaths occurred at later time points except in the
vehicle control group, where there was poor tumor control. Overall
survival curve analysis revealed that animals that were preconditioned
had significantly decreased survival in comparison to animals that did
not receive this regimen (hazard ratio [HR] = 3.059 [1.011; 9.258] pre-
conditioning versus vehicle, p < 0.05) (Figure 2B).
Assessment of survival in different groups indicated that precondi-
tioning was responsible for all deaths that occurred at early time
points (before day 24). In comparison to oncolytic adenovirus +
TILs or preconditioning + TILs (the two best groups), survival
was poorer in animals that received all three treatments
(preconditioning + oncolytic adenovirus + TILs) (Figure 2C). Pre-
conditioning also increased the HR for death (HR = 9.134 [1.37;
60.88] preconditioning + oncolytic adenovirus + TILs versus onco-
lytic adenovirus + TILs; Figure 2C). In contrast, adenovirus therapy
performed significantly better compared with the vehicle controlMolecula(p < 0.05), preconditioning alone (p < 0.01),
and the triple combination (p < 0.05) (Fig-
ure 2C). Moreover, oncolytic adenovirus was
most consistent with regard to survival; the first
casualty did not occur until day 64 (Figure 2C).
Repeated Administration of Adenovirus
Enables Long-TermHapT1 Tumor Control in
Hamsters
As a secondary endpoint, we recorded tumor
growth in the survival experiment to assess if
adenovirus therapy and/or preconditioning are
able to provide long-term tumor control and ef-ficacy. By day 6, we observed overall tumor growth separating be-
tween the two main therapeutic groups, hamsters that received
vehicle and hamsters that received lymphodepleting preconditioning
regimen (Figure 2D). This was likely caused by the antitumor effects
of cyclophosphamide and fludarabine. Of note, dead animals were
censored from the tumor size graph. Thus, observing only tumor
size is misleading, since there were many treatment-related deaths
in these groups as discussed in the previous paragraph. Much like
our main efficacy experiment (Figure 1B), TIL therapy added little
efficacy compared to the vehicle. In contrast, when oncolytic adeno-
virus injections were added, there was a prominent effect on thera-
peutic efficacy (Figure 2D).
If the animals survived preconditioning (and 53% did not), tumor
sizes were smaller during the first 25 days (all preconditioning thera-
pies versus vehicle, p < 0.05; Figure 2D). Nevertheless, precondition-
ing alone did not provide lasting tumor control (Figure S3). In parallelr Therapy Vol. 26 No 9 September 2018 2245
Figure 2. Overall Survival and Antitumor Efficacy in
Hamsters Treated Systemically with TILs and
Locally with Oncolytic Adenovirus
(A) Hamsters with 5-day-old subcutaneous HapT1
tumors received a lymphodepleting regimen consisting of
cyclophosphamide (550 mg/kg) and fludarabine
(100 mg/kg) or saline intraperitoneally (i.p.). 1  108 VPs
oncolytic adenovirus (OAd) coding for human IL-2 and
TNF-a or PBS was injected intratumorally (i.t.) on day 1
and repeated 4 times in intervals of 4–6 days. Three
additional rounds of 5 injections were repeated until the
end of the experiment. Tumor-infiltrating lymphocytes
(TILs) or RPMI was injected i.p. after the first virus injec-
tion. Tumors were measured and animals (n = 4–5) were
followed until day 121. (B) Overall survival of animals
receiving vehicle, no preconditioning (including TIL and
oncolytic adenovirus + TILs), or preconditioning (including
preconditioning alone, preconditioning + TILs, and
preconditioning + oncolytic adenovirus + TILs). (C) Overall
survival of the different therapeutic groups. (D) Antitumor
efficacy from the different therapeutic groups. Data are
presented as mean + SEM; *p < 0.05, **p < 0.01, ***p <
0.001, and ****p < 0.0001.
Molecular Therapyto what has been seen in humans, the combination of TILs with lym-
phodepletion resulted in good tumor control compared to hamsters
that received only preconditioning (preconditioning versus
preconditioning + TILs, p < 0.05). Repeated administration of onco-
lytic adenovirus in TIL-treated animals without lymphodepletion al-
lowed long-term tumor control, as seen in individual tumor growth
curves (Figure S3).
AdenovirusesCoding for IL-2 andTNF-aAchieve theBest Tumor
Control in Mice Treated with Genetically Modified T Cells
Using another adoptive T cell therapy approach, we treated immuno-
competent mice bearing B16.OVA tumors with TCR transgenic oval-
bumin-specific T (OT-I) cells. Despite the fact that human serotype 5
adenovirus does not replicate in mice and, thus, oncolysis cannot be
taken into consideration, this model enables the evaluation of the ef-
fects of the cytokines coded by adenovirus and testing of our hypoth-2246 Molecular Therapy Vol. 26 No 9 September 2018esis using a genetically modified T cell therapy
approach (Figure 3A). Until day 4, all therapies
resulted in similar tumor control (Figure 3B).
Yet, after day 4, OT-I cell transfer alone was
only able to delay tumor growth moderately,
while the addition of adenovirus and/or lympho-
depleting preconditioning therapies improved
markedly the overall antitumor efficacy of
OT-I cell transfer (Figure 3B).
Combining adenovirus therapy with OT-I cell
transfer resulted in the best efficacy, with statis-
tical significance when compared with the lym-
phodepleted group (OT-I + adenovirus versuspreconditioning + OT-I, p < 0.01; Figure 3B). Moreover, the combi-
nation of adenovirus or preconditioning with OT-I cell transfer
induced effective steady tumor control, contrasting with the vehicle
andOT-I control groups (Figures 3C and 3D). As previously observed
in hamsters (Figure 1B), triple treatment was not superior to double
treatments (Figures 3B and 3G).
Adenovirus Therapy and Lymphodepleting Preconditioning
Drive the Accumulation of Effector Cells and Convert APCs
toward a Proinflammatory Status in the Tumor
Microenvironment
To investigate the mechanism of action underlying the efficacy seen,
we assessed immune cell populations within the tumor. Animals
treated with OT-I cells showed a small increase in CD3+ T cells (Fig-
ure 4A), CD3+CD8+ T cells (Figure 4B), CD11c+ dendritic cells (Fig-
ure S4), and CD11c+CD86+ dendritic cells (Figure 4C) at the tumor
Figure 3. Antitumor Efficacy of Systemically Infused OT-I Cells and Adenovirus Therapy in Mice
(A) Mice with 7-day-old subcutaneous B16.OVA tumors received a lymphodepleting regimen consisting of cyclophosphamide (300 mg/kg) and fludarabine (100 mg/kg) or
saline intraperitoneally (i.p.). 1 108 VPs adenovirus (Ad) coding for murine IL-2 and TNF-a in a ratio of 1:1 or PBSwas injected intratumorally (i.t.) on day 1. OT-I cells or RPMI
was injected i.p. following virus injection. (B) Tumors were measured and animals (n = 7–10) were followed until day 11. (C–G) Individual tumor growth curves from different
treatment groups: vehicle (C), OT-I (D), adenovirus + OT-1 (E), preconditioning + OT-I (F), and preconditioning + adenovirus + OT-I (G). Data are presented as mean + SEM;
**p < 0.01 and ****p < 0.0001.
www.moleculartherapy.orgsite. Notably, in the groups with the best efficacy (adenovirus + OT-I
and preconditioning + OT-I), all differences were significant versus
controls (Figures 4A–4C). All of these cell populations, with the
exception of CD11c+ dendritic cells (Figure S4), were equally signif-
icant in the triple group in comparison to controls. The expression
levels of CD86 maturation marker in dendritic cells followed
the same trend, with prominent increases in the three main thera-
peutic groups (OT-I + adenovirus, preconditioning + OT-I, and
preconditioning + adenovirus + OT-I) compared to the vehicle group
(Figure 4D). Interestingly, the biological effects of preconditioning
were quite similar to those of the adenovirus coding for IL-2 and
TNF-a. However, the triple combination did not have any additive
effects over the double treatments.
Next, we evaluated the intratumoral levels of T helper 1 (Th1)-type
proinflammatory cytokines (mIL-2, mTNF-a, and interferon gamma
[mIFNg]) in endpoint B16.OVA tumors. Relative to the vehicle
group, the levels of intratumoral mIL-2 were upregulated at least5.1-fold in animals that received lymphodepleting preconditioning
and/or adenovirus (Figure 4E). This was especially prominent in
the latter group, where this upregulation was significant relative to an-
imals in the vehicle (p < 0.05) and OT-I therapy (p < 0.05) groups
(Figure 4E). mTNF-a and mIFNg were 5.5-fold and 3.5-fold
increased, respectively, in animals that received the combination of
OT-I and adenovirus versus vehicle (Figures 4F and 4G). In contrast,
animals that received lymphodepleting preconditioning and OT-I
therapy showed a moderate or low increase of intratumoral levels
of these cytokines (Figures 4F and 4G).
The addition of adenovirus to animals that received preconditioning
and OT-I treatment resulted in surprisingly low levels of mTNF-a
and mIFNg at the tumor site (Figures 4F and 4G). Interestingly,
except mTNF-a, the same trend was observed for all Th1-type cyto-
kines in animals that received only OT-I therapy (Figures 4E–4G).
Particularly, mIFNg was significantly upregulated in animals that
received preconditioning + OT-I cells compared with the tripleMolecular Therapy Vol. 26 No 9 September 2018 2247
Figure 4. Immune Characterization and Cytokine Content of Endpoint B16.OVA Murine Tumors
Day 13 endpoint tumors (n = 4–8) were analyzed for the presence of (A) CD3+ T cells, (B) CD3+CD8+ T cells, (C) CD11c+CD86+mature DCs, and (D) CD86 expression levels.
Tumors (n = 2–8) were analyzed for (E) mIL-2, (F) mTNF-a, and (G) mIFNg. (H) Pooled Th1-type cytokines. All values from cytokine content are normalized to the mean vehicle
value. Data are presented as mean + SEM; *p < 0.05, **p < 0.01, and ***p < 0.001.
Molecular Therapytherapy and OT-I therapy (Figure 4G). Nevertheless, when we pooled
all Th1-type response cytokines, we observed that animals that
received adenovirus and OT-I cells had their Th1 cytokines increase
1.3-fold over animals that received the lymphodepleting regimen and
OT-I cells (Figure 4H).
Lymphodepleting Chemotherapy Causes Toxicity to Vital
Tissues
To investigate the effects of the lymphodepleting chemotherapeutics
on different organs, we examined vital organs for pathological
changes. In a setting where TIL therapy was not administered, we
observed a drastic decrease in lymphocytes, neutrophils, and platelets
in lymphodepleted animals compared to the vehicle and oncolytic
adenovirus groups (Figure 5A). Heart tissue from preconditioned
hamsters showed degenerative changes compatible with cardiac
toxicity (Figure 5A). In contrast, adenovirus therapy resulted in
only a mild decrease of platelets (vehicle versus oncolytic adenovirus,
p < 0.05) but nomajor changes in lymphocytes or neutrophils (vehicle
versus oncolytic adenovirus, ns; Figure 5A).
Extensive toxic effects of lymphodepleting preconditioning were
also seen in mice. The use of cyclophosphamide and fludarabine
caused acute or severe degeneration in the cardiac muscle (Figures2248 Molecular Therapy Vol. 26 No 9 September 20185B and 5C). Furthermore, the lungs of the same animals had
numerous alveolar and interstitial macrophages (Figure 5B). In addi-
tion, there was multifocal thickening and hyalinization of small pul-
monary vessels, indicating degeneration (Figures 5B and 5C). These
findings were observed to a minimal extent in mice treated with
adenovirus. Nevertheless, the addition of adenovirus to lymphode-
pleted animals did seem to result in vascular degeneration in the lungs
(Figures 5B and 5C). Thus, even though the triple combination did
not add to efficacy or appealing immunological parameters, it did
seem to add to toxicity.
When we assessed the blood serum for inflammatory cytokines, we
found that mIL-2, mIL-6, mTNF-a, andmIFNgwere highly increased
in animals that received lymphodepleting preconditioning and OT-I
therapy compared with the rest of the groups (Figure S5).
DISCUSSION
This study reports that lymphodepleting preconditioning may not be
required for effective ACT of solid tumors if replaced by an oncolytic
adenovirus coding for IL-2 and TNF-a. We have focused our efforts
in developing a viral platform that supports ACT in the absence of
toxic high-dose chemotherapy lymphodepleting preconditioning reg-
imens and high-dose IL-2 postconditioning. While our previous work
Figure 5. Treatment-Related Systemic Adverse
Events in Hamster and Mouse Tissues
(A) Hamsters that did not receive TIL therapy but were
administered the vehicle, oncolytic adenovirus therapy, or
lymphodepleting preconditioning (n = 5) were sacrificed at
day 4, and blood was collected for lymphocyte, neutro-
phil, and platelet counting. The heart was collected for
cardiac toxicity assessment through H&E staining. (B)
Mice from different treatment groups (n = 7–10) were
sacrificed on day 13 and the heart and lungs were
collected for H&E staining and toxicity assessment. (C)
20-magnified 4- to 5-mm thickness H&E-stained
mouse lung and heart sections; Arrows indicate signifi-
cant structural changes in the tissue. Data are presented
as mean + SEM; *p < 0.05, **p < 0.01, ***p < 0.001, and
****p < 0.0001.
www.moleculartherapy.orgdemonstrated that vectorization of IL-2 by an oncolytic adenovirus
can replace high-dose systemic IL-2 postconditioning while reducing
toxicity,23 lymphodepleting preconditioning remained an open issue
to be solved. Using the same animal tumor models and two different
methods of ACT, the combination of adenovirus with TIL therapy re-
sulted in prolonged survival and comparable (or superior) antitumor
responses to those seen in animals receiving lymphodepleting precon-
ditioning. Similar observations have beenmade in a clinical trial using
a non-oncolytic adenovirus coding for IFNg and TIL therapy in pa-
tients with metastatic melanoma that did not receive precondition-
ing.22 Our experiments extend these findings to an oncolytic virus,
which, unlike replication-incompetent adenovirus vectors, allows tu-
mor-selective replication, enhanced infectivity in advanced malig-
nancies, and tumor cell oncolysis. Moreover, IFNg as a transgene
may be problematic with regard to the induction of rapid immuno-
suppression through Programmed cell death protein 1 (PD-1).22
Of note, our results show that lymphodepleting preconditioning may
be counterproductive from a survival perspective. At a systemic level,Moleculathe use of a lymphodepleting regimen could
possibly harm the development of meaningful
long-term systemic antitumor immunity and
memory responses, because the relevant cells
may be depleted. Accordingly, splenocytes
from preconditioned hamsters had decreased
ability to kill HapT1 tumor cells relative to
spleens from hamsters that received oncolytic
adenoviruses and TILs (Figure 1C), possibly
caused by a reduction in the overall percentage
of CD8+ and CD4+ cells (Figure S2). Moreover,
the reconstitution of highly suppressive
myeloid-derived suppressor cells (MDSCs)
may also account for this result, since these cells
have been shown to repopulate the spleens
from mice that have undergone lymphodeple-
tion.24 Interestingly, the triple combination
(preconditioning + oncolytic adenovirus +TILs) did not result in favorable survival or efficacy. Even though
oncolytic viruses have been proposed to have synergy with immuno-
suppressive drugs in some animal models, through increased virus
replication,25,26 the induction of tumor-specific immunity may be
compromised by immunosuppression. This would explain why the
triple combination seemed worse than the doublets. In addition, sple-
nocytes from hamsters treated with oncoclytic adenovirus therapy
were capable of achieving the highest HapT1 killing regardless of
the comparable levels of splenic CD4+ and CD8+ cells in the different
therapies (vehicle, TILs, and oncolytic adenovirus + TILs). A higher
percentage of tumor-specific T cells could possibly explain this occur-
rence, since this has been demonstrated to be a splenic feature of an-
imals treated with adenovirus therapy.27
One of the major challenges in ACT of solid tumors with TILs or
gene-modified T cells is the poor infiltration of transferred T cells
into the tumor microenvironment.8 In humans, melanoma and
pancreatic cancer (the tumor types assessed in this study) are no
exception, with the presence of TILs typically associated with longerr Therapy Vol. 26 No 9 September 2018 2249
Molecular Therapysurvival.28,29 We have shown that IL-2 and TNF-a can recruit natural
killers and T cells to the tumor when produced from oncolytic adeno-
viruses.19–21,23,30,31 This effect on trafficking could explain part of the
good efficacy seen here. Additionally, preclinical work has proposed
that host lymphodepletion associated the increased proliferation of
CD8+ T cells with high antitumor efficacy in lymphodepleted
hosts.32,33 Yet, and concordantly with our previous work,20,30 we
found that hamsters that achieved high tumor control had a higher
prevalence of CD4+ over CD8+ cells independently of the TIL com-
bination treatment (Figures 1B and 1). Since Th1 CD4+ T cells are
known to exert potent effector functions in vivo,34 it seems possible
that this phenotype may comprise the majority of the CD4+ cells in
tumors that responded better to therapy. Because the tumor microen-
vironment often dictates if CD4+ cells become effector or suppres-
sor,34 one can hypothesize that the modulatory effects of the treat-
ments may have favored the differentiation of CD4+ cells into a
Th1 phenotype through adenovirus infection,35 the effects of IL-2,36
or lymphodepletion.37 In addition, MHC class II upregulation (a den-
dritic cell [DC] marker) in the draining lymph node may have
contributed to the antitumor efficacy in hamsters treated with onco-
lytic adenovirus and TILs, given that this is required for effective
CD4+ cell priming.20,30 Nonetheless, this cannot be confirmed at pre-
sent due to the lack of anti-hamster reagents.
In the B16.OVA tumor model, high antitumor efficacy was associated
with the overall increase in CD3+ and CD8+ T cells, regardless of the
therapeutic group (Figures 4A and 4B). This phenomenon may have
arisen from the increased availability of IL-7 and IL-15 and depletion
of Tregs and MDSCs, which are reported to contribute to the prolif-
eration, activity, and lasting antitumor responses of effector T cells in
lymphopenic mice.24,38 Intratumoral APCs followed the same pattern
as CD11c+ and their maturation marker, CD86, was increasingly ex-
pressed in lymphodepleted mice (Figure S4; Figures 4C and 4D). This
result is consistent with Salem et al.,39 who proposed that cyclophos-
phamide-induced lymphopenia promotes the expansion of dendritic
cells. Moreover, CD86 is a costimulatory molecule that has been
linked to CD8+ T priming, activation, and survival,40 which are likely
related to increased antitumor activity of CD8+ T cells. Interestingly,
our experiments and others41 showed that the same events were
observed in lymphoreplete mice that received adenovirus therapy.
Infection of B16.OVA tumors with IL-2- and TNF-a-coding adeno-
virus in the context of OT-I cell transfer actively recruits CD8+
T cells to the tumor site,19,21 and it triggers pathogen signaling that
may have enhanced APC interaction with CD8+ T cells through
CD86.17 Thus, the effects of adenovirus therapy and lymphodepletion
may be similar at the tumor, even if the mechanisms are different.
Immunostimulatory cytokines also play a critical role in orchestrating
an effective immune response against the tumor, either by interaction
with immune cells or direct contact with cancer cells.31,42 Cancer cells
have the ability to exploit the absence of proinflammatory cytokines
as one mechanism of evasion from the immune system.31 Sometimes
the tumor microenvironment corrupts the physiological proinflam-
matory expression of cytokines, which is dynamic and often high level2250 Molecular Therapy Vol. 26 No 9 September 2018but short duration, into a chronic low-level expression, which is a
recognized carcinogenic factor.31
Adenoviruses are advantageous carriers of cytokines, and we have
previously shown in an ACT setting that the addition of IL-2 and
TNF-a, at the tumor site, supports antitumor T cells and, thus, cir-
cumvents local tumor immunosuppression.15,19,21,42 Accordingly,
increased acute production of Th1 proinflammatory cytokines was
seen, likely derived from virus transgenes, while increased IFNg
may be attributed to the increase in CD8+ T cell activity in the tumor
(Figures 4E and 4F). Notably, TNF-a and IFNg were highly upregu-
lated in the highest efficacy group (adenovirus with OT-I therapy;
Figures 4F and 4G), both of which are required for T cell-mediated
B16 tumor rejection.43,44 Of note, depletion of immune cells (by lym-
phodepletion) might have impaired the development of T cell immu-
nity against adenovirus at the tumor site. As a result, this may have
limited the production of IFNg and, consequently, resulted in lower
levels of Th1-type proinflammatory cytokines in the triple combina-
tion group (Figure 4H).
While there is no question that lymphodepleting preconditioning en-
hances the effectiveness of ACT, its safety issues have been a concern,
limiting its use in frail cancer patients.4,5,11–13 Considering that the
large majority of ACT clinical trials use chemotherapy-based lym-
phodepleting regimens, especially in the context of solid tumors, we
employed the same drugs here, high-dose cyclophosphamide (an al-
kylating agent) and fludarabine (a nucleoside analog).45 The combi-
nation of these two agents kills the majority of white blood cells in
the patient or animal, preferentially those from lymphoid lineage
cells, rendering the subject immunosuppressed. Consequently, and
as observed in humans,4,5,11–13 blood from lymphodepleted hamsters
that were not administered TIL therapy revealed an abrupt decrease
of lymphocytes, neutrophils, and platelets (Figure 5A). While the
decreased numbers of neutrophils and lymphocytes exposes the
host to endogenous and exogenous pathogens, the low platelet count
impedes blood clotting, increasing the risk of internal bleeding. We
suspect that these conditions may have led to a high number of casu-
alties present at an early time point in our hamster experiments. Pre-
conditioning also causes mortality in humans,11,12 but at a lower rate
because humans are monitored more carefully; infections are treated
with antibiotics, leukopenia can be treated with granulocyte colony-
stimulating factor (GCSF), platelets or erythrocytes can be trans-
ferred, and intensive care is available.5,11–13
At a cellular level, cyclophosphamide is metabolized into toxic me-
tabolites that damage myocytes, leading to cardiac dysfunction and
degeneration.45 As expected, this finding was particularly prominent
in mice that received lymphodepleting preconditioning, which
interestingly also demonstrated signs of hypertension with endothe-
lial cell remodeling and hypertrophism (lungs; Figure 5C). These
events may have resulted from multiple factors, including the direct
effect of cyclophosphamide, cardiac dysfunction46,47 and, as a by-
product of increased levels of IL-6,48 TNF-a,49 and IFNg50 inflam-
matory cytokines (Figure S5). Moreover, because macrophages are
www.moleculartherapy.orgdirectly regulated by activated T cells,51 their increase in combina-
tion with systemic inflammation possibly contributed to the numer-
ical increase in interstitial macrophages and, thus, hypertension in
lungs from lymphodepleted mice. In contrast, adenovirus therapy
is well tolerated in humans, usually resulting in only mild to mod-
erate adverse events,22,26 including fatigue, fever, and flu-like symp-
toms. In line with previous observations,23 animals treated with
adenovirus did not show significant tissue alterations in any of
the two different species. Furthermore, it appears unlikely that
this approach would potentiate a cytokine release syndrome, a
toxicity arising from the use of gene-modified T cells for solid tu-
mors.1 An important aspect of the oncolytic adenovirus design is
that virus replication is tightly linked to transgene expression.20
Therefore, the adenovirus will replicate and transgenes will be ex-
pressed as long as tumor cells are present. This has been confirmed
in animals20,23 and humans,52 where cytokine shedding to the blood
serum has remained minimal.
To summarize, our study suggests that oncolytic adenovirus coding
for IL-2 and TNF-a is an attractive alternative to host lymphodeple-
tion in solid tumor ACT protocols. Compared to lymphodepletion,
the virus approach demonstrates a mild toxicity profile and high
antitumor efficacy, which fundamentally determine the use of this
modality in the clinic. Importantly, it was established that there is
no rationale for using lymphodepletion together with the oncolytic
adenovirus approach in ACT patients. A phase I clinical trial is under-
way, where melanoma patients receiving TIL therapy are treated with
oncolytic adenovirus (Ad5/3-E2F-d24-hTNF-a-IRES-hIL-2, also
known as TILT-123). No lymphodepletion will be used in this trial.
MATERIALS AND METHODS
Cell Lines and Viruses
The experiments performed in animals involved the use of HapT1,
HAK, DDT1-MF2, and B16.OVA cell lines obtained and cultured
as previously reported.17,19,20,23,30,42,53 Replication-deficient Ad5-
CMV-mTNF-a, Ad5-CMV-mIL-2, and oncolytic Ad5/3-E2F-d24-
hTNF-a-IRES-hIL-2 were constructed and obtained as previously
described.19,20
Animal Experiments
All animal protocols were carried out in agreement with the experi-
mental animal committee of the University of Helsinki (Helsinki,
Finland) and the Provincial Government of Southern Finland. 5- to
6-week-old immunocompetent male Golden Syrian Hamsters
(HsdHan:AURA, Envigo, Huntington, UK) were implanted subcuta-
neously with 4  106 HapT1 cells in both flanks. For the short-term
efficacy hamster experiment, tumors were grown for 5 days and ham-
sters were randomized into 5 therapeutic groups (n = 5–6). Following
virus treatment, hamsters were followed for 28 days and their tumors
were measured with a digital caliper. Alternatively, after virus treat-
ment initiation, hamsters were followed until day 4 and humanely
sacrificed for the collection of organs for histopathology and blood
for white blood cell and platelet counting (n = 5). For the hamster sur-
vival experiment, tumors were grown for 5 days and hamsters wererandomized into therapeutic groups (n = 4–5). Upon virus treatment,
hamsters were followed for 121 days and their tumors were measured
with a digital caliper. Endpoint criteria included tumor size limit
(maximum diameter of 22,00 mm), skin ulcerations, visible decrease
of well-being, or sudden death. For the testing of different doses of
lymphodepleting chemotherapy (Figure S6), tumors were grown for
7 days, after which cyclophosphamide was administered. After
2 days, hamsters were sacrificed and the blood was collected for white
blood cell counting (n = 3).
Similarly, 4- to 6-week-old immunocompetent C57BL/6 female mice
(Harlan Laboratories, Indianapolis, IN, USA) were implanted subcu-
taneously with 0.25  106 B16.OVA cells in the right flank. Tumors
were grown for 7 days and mice were randomized into 5 groups
(n = 7–10). Following virus treatment, mice were followed for
13 days and their tumors were measured with a digital caliper.
All animals were humanely sacrificed and their blood and tumors
were collected for blood count analysis and flow cytometry, respec-
tively. Selected organs were also collected for histopathology. In all ex-
periments, the tumor volume was obtained as 0.52 length width2
formula. Normalized tumor volume was obtained as percentage of
daily tumor volume relative to day 1 tumor volume.Lymphodepleting Preconditioning Regimen and Virus
Treatments
Lymphodepleting preconditioning regimen was performed with
cyclophosphamide (Sendoxan, Baxter, Deerfield, IL, USA) and flu-
darabine (Fludaribis, Actavis, Parsippany-Troy Hills, NJ, USA). After
testing different doses of cyclophosphamide (550, 450, 350, and
250 mg/kg) with 100 mg/kg fludarabine for the depletion of white
blood cells (Figure S6), hamsters received a single injection of
9 mg/mL saline (Braun, Aschaffenburg, Germany) or 550 mg/kg
cyclophosphamide (maximum solubility 50 mg/mL) on day 1, fol-
lowed by a single injection of 9 mg/mL saline or 100 mg/kg fludara-
bine on day 0. Moreover, hamsters were injected intratumorally with
50 mL PBS or 1 108 viral particles (VPs) per tumor of oncolytic Ad5/
3-E2F-d24-hTNF-a-IRES-hIL-2 (also known as TILT-123) on day 1.
Depending on the experiment, virus treatments were repeated on
days 5, 9, 14, and 20 or continued 3 more rounds in blocks of 5 injec-
tions. Similarly, mice received a single injection of 9 mg/mL saline or
300 mg/kg cyclophosphamide on day 1 followed by a single
injection of 9 mg/mL saline or 100 mg/kg fludarabine on day 0.
The following day, mice were administered intratumorally only
once with 50 mL PBS or 1  108 VPs/tumor Ad5-CMV-mIL-2 and
Ad5-CMV-mTNF-a (1:1 ratio).Adoptive Cell Transfer
Hamster TILs were obtained using a culturing method previously
described by our group.20,23,30 Following the first virus treatment,
hamsters in the short-term efficacy experiment received 4  106
TILs intratumorally, while hamsters in the survival experiment
received 50  106 TILs intraperitoneally.Molecular Therapy Vol. 26 No 9 September 2018 2251
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were obtained using a culturing method previously described by
our group.17,19,23,42 After 9 days culturing, 1 106 OT-I cells were in-
jected intraperitoneally in mice following virus treatment.
Cytotoxicity Assay
HapT1, HAK, and DDT1-MF2 were seeded at density of 1 104 cells
and co-cultured with 20  104 pooled splenocytes (from each thera-
peutic group) per well in 96-well plates, according to the protocols
previously established.20,30
Blood Collection, Counting, and Histopathology
Blood from hamsters was collected in heparinized 1-mL tubes
(Greiner Bio-one, Kremsmünter, Austria). The neutrophil, lympho-
cyte, and platelet counts were obtained using ADVIA 2120i (Siemens,
Erlangen, Germany). Alternatively, after the collection of blood from
hamsters treated with different doses of chemotherapy, red blood cells
were lysed with ammonium-chloride-potassium (ACK) lysing buffer
(Thermo Fisher Scientific, Waltham, MA, USA), and white blood
cells were analyzed through a BD Accuri C6 flow cytometer (BD Bio-
sciences, San Jose, CA, USA) (Figure S6). Additionally, tissue samples
from heart, lungs, and liver were prepared for H&E staining, as pre-
viously described.20,23 Histopathological changes were assessed by a
veterinary pathologist.
Cytokine Bead Array
Blood serum and homogenized snap-frozen tumor fragments were
processed and stored at 80C, as previously described.42 Levels of
mIL-2, mTNF-a, mIFNg, and mIL-6 were measured using the CBA
mouse Th1/Th2/Th17 kit (560485, BD Biosciences, San Jose, CA,
USA) and BD Accuri C6 flow cytometer with FCAP Array software
(BD Biosciences, San Jose, CA, USA). The levels obtained were
normalized against the total protein content of the samples.
Flow Cytometry
As previously described,19,20,23,30,42 tumors, spleens, and lymph nodes
collected from animals were prepared into a single-cell suspension
and stored at 80C. Hamster and murine organs were stained as
previously reported.17,19,20,23,30,42,53 1,000 to 100,000 events were
acquired during analysis on a BD Accuri C6 flow cytometer with
CSampler software (BD Biosciences, San Jose, CA, USA).
Statistical Analysis
Statistical comparisons on log-transformed normalized tumor vol-
umes from the different therapeutic groups were assessed using linear
mixed models with SPSS version 24 (IBM, North Castle, NY, USA).
Differences between tumor samples or cell viability and survival
were obtained with unpaired Student’s t test with Welch’s correction
and Kaplan-Meier survival analysis, respectively, using GraphPad
Prism 7.04 software (GraphPad, La Jolla, CA, USA).
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